[{"id":"b80fb1d9-c22f-4356-804c-6c0a54eb0ff6","acronym":"SENTRY","url":"https://clinicaltrials.gov/study/NCT04562389","created_at":"2021-01-29T07:21:26.651Z","updated_at":"2025-02-25T16:45:11.264Z","phase":"Phase 3","brief_title":"Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis","source_id_and_acronym":"NCT04562389 - SENTRY","lead_sponsor":"Karyopharm Therapeutics Inc","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • Xpovio (selinexor)"],"overall_status":"Recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 03/11/2021","start_date":" 03/11/2021","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 03/01/2028","study_completion_date":" 03/01/2028","last_update_posted":"2025-02-05"},{"id":"40f5121b-bb06-4c08-8167-45765aada070","acronym":"KCP-8602-801","url":"https://clinicaltrials.gov/study/NCT02649790","created_at":"2021-01-17T17:34:58.356Z","updated_at":"2024-07-02T16:35:00.978Z","phase":"Phase 1/2","brief_title":"Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications","source_id_and_acronym":"NCT02649790 - KCP-8602-801","lead_sponsor":"Karyopharm Therapeutics Inc","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • dexamethasone • Inqovi (decitabine/cedazuridine) • eltanexor (KPT-8602)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 277","initiation":"Initiation: 01/01/2016","start_date":" 01/01/2016","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-24"},{"id":"cc43e353-d912-4b11-8947-43a4ef4b102a","acronym":"SINE","url":"https://clinicaltrials.gov/study/NCT02199665","created_at":"2021-01-18T10:17:08.750Z","updated_at":"2024-07-02T16:35:03.805Z","phase":"Phase 1","brief_title":"Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT02199665 - SINE","lead_sponsor":"University of Chicago","biomarkers":" CRBN","pipe":"","alterations":" ","tags":["CRBN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xpovio (selinexor) • carfilzomib • dexamethasone • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 06/12/2014","start_date":" 06/12/2014","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 12/25/2024","study_completion_date":" 12/25/2024","last_update_posted":"2024-05-14"},{"id":"2d1c3ca8-7296-43e4-82a1-3a09a7010bbd","acronym":"C-SMART","url":"https://clinicaltrials.gov/study/NCT04534725","created_at":"2021-01-18T21:42:26.535Z","updated_at":"2024-07-02T16:35:39.087Z","phase":"Phase 3","brief_title":"COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;","source_id_and_acronym":"NCT04534725 - C-SMART","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xpovio (selinexor) • LENZ (lenzilumab)"],"overall_status":"Completed","enrollment":" Enrollment 441","initiation":"Initiation: 12/17/2020","start_date":" 12/17/2020","primary_txt":" Primary completion: 11/28/2022","primary_completion_date":" 11/28/2022","study_txt":" Completion: 04/19/2023","study_completion_date":" 04/19/2023","last_update_posted":"2023-08-24"},{"id":"b68c6614-ac98-44cb-a0a7-526b8d8fa2d0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02120222","created_at":"2021-01-18T09:49:01.639Z","updated_at":"2024-07-02T16:35:51.513Z","phase":"Phase 1","brief_title":"Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery","source_id_and_acronym":"NCT02120222","lead_sponsor":"Kari Kendra","biomarkers":" BRAF • IL2","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K","tags":["BRAF • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xpovio (selinexor)"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 08/22/2014","start_date":" 08/22/2014","primary_txt":" Primary completion: 04/08/2018","primary_completion_date":" 04/08/2018","study_txt":" Completion: 04/08/2018","study_completion_date":" 04/08/2018","last_update_posted":"2023-04-04"},{"id":"6c9e66a0-5495-4994-8775-934932402521","acronym":"","url":"https://clinicaltrials.gov/study/NCT01607905","created_at":"2021-01-18T06:52:55.744Z","updated_at":"2024-07-02T16:35:56.972Z","phase":"Phase 1","brief_title":"Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer","source_id_and_acronym":"NCT01607905","lead_sponsor":"Karyopharm Therapeutics Inc","biomarkers":" EGFR • KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["EGFR • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xpovio (selinexor)"],"overall_status":"Completed","enrollment":" Enrollment 192","initiation":"Initiation: 06/18/2012","start_date":" 06/18/2012","primary_txt":" Primary completion: 03/15/2016","primary_completion_date":" 03/15/2016","study_txt":" Completion: 03/15/2016","study_completion_date":" 03/15/2016","last_update_posted":"2023-01-26"},{"id":"726020ef-34b5-49a4-94e1-59588dc6aeb5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02025985","created_at":"2021-01-18T09:16:39.237Z","updated_at":"2024-07-02T16:35:56.995Z","phase":"Phase 2","brief_title":"Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies","source_id_and_acronym":"NCT02025985","lead_sponsor":"Karyopharm Therapeutics Inc","biomarkers":" MUC16","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xpovio (selinexor)"],"overall_status":"Completed","enrollment":" Enrollment 116","initiation":"Initiation: 04/09/2014","start_date":" 04/09/2014","primary_txt":" Primary completion: 01/24/2017","primary_completion_date":" 01/24/2017","study_txt":" Completion: 03/29/2017","study_completion_date":" 03/29/2017","last_update_posted":"2023-01-26"}]